Takuya Matsushita
Overview
Explore the profile of Takuya Matsushita including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
112
Citations
1639
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Yata T, Sato G, Ogawa K, Naito T, Sonehara K, Saiki R, et al.
Cell Genom
. 2025 Feb;
5(3):100776.
PMID: 39986280
Neuromyelitis optica spectrum disorder (NMOSD) is a rare autoimmune disease characterized by optic neuritis and transverse myelitis, with an unclear genetic background. A genome-wide meta-analysis of NMOSD in Japanese individuals...
2.
Kawamura N, Matsushita T, Itamiya H, Sugita R, Yamazaki T
J Forensic Sci
. 2024 Nov;
70(1):117-131.
PMID: 39540339
The occurrences of various illegal activities on beaches require effective geological and environmental investigation methods. Among these methods, the room-temperature magnetic analysis of soils and sediments represents a nondestructive investigation...
3.
Watanabe M, Masaki K, Tanaka E, Matsushita T, Isobe N
Cureus
. 2024 Nov;
16(11):e73205.
PMID: 39534550
Eculizumab, a monoclonal antibody against complement C5, has been approved to prevent neuromyelitis optica spectrum disorder (NMOSD) relapse. Although complement activation leads to neuroinflammation and tissue necrosis in NMOSD attacks,...
4.
Nonaka T, Ae R, Kosami K, Tange H, Kaneko M, Nakagaki T, et al.
Diagnostics (Basel)
. 2024 Nov;
14(21).
PMID: 39518392
Background/objectives: Sporadic Creutzfeldt-Jakob disease (sCJD) is a fatal neurodegenerative disorder traditionally diagnosed based on the World Health Organization (WHO) criteria in 1998. Recently, Hermann et al. proposed updated diagnostic criteria...
5.
Watanabe M, Isobe N, Niino M, Nakashima I, Matsushita T, Sakai Y, et al.
Neurology
. 2024 Oct;
103(10):e209992.
PMID: 39475688
Background And Objectives: All 4 previous nationwide surveys of multiple sclerosis (MS) in Japan were conducted before the discovery of anti-aquaporin-4 (AQP4) antibodies; thus, neuromyelitis optica spectrum disorder (NMOSD) was...
6.
Yamamoto T, Fujito R, Chadani Y, Kashibayashi T, Kamimura N, Tsuda A, et al.
Geriatr Gerontol Int
. 2024 May;
24(7):693-699.
PMID: 38810991
Aim: This study aimed to investigate the improvement in gait velocity variability after cerebrospinal fluid (CSF) elimination, and the association between gait velocity variability and gait and cognitive impairment in...
7.
Sato T, Nagai M, Watanabe O, Misu T, Takenouchi N, Ohkubo R, et al.
J Neurol
. 2024 Mar;
271(6):3471-3485.
PMID: 38430272
Human T-cell leukemia virus type 1 (HTLV-1)-associated myelopathy/tropical spastic paraparesis (HAM/TSP) is a chronic neurodegenerative disease. This multicenter, randomized phase 3 study evaluated the efficacy and safety of 0.3 mg/kg...
8.
Nakayama T, Nakajima F, Yamasaki H, Matsushita T
J Phys Ther Sci
. 2023 Jul;
35(7):515-519.
PMID: 37405184
[Purpose] We aimed to examine the correlation between the knee extension angles in the sitting and supine positions measured using ImageJ software. [Participants and Methods] A total of 50 legs...
9.
Leppert D, Watanabe M, Schaedelin S, Piehl F, Furlan R, Gastaldi M, et al.
J Neurol Neurosurg Psychiatry
. 2023 Apr;
94(9):726-737.
PMID: 37076291
Background: Granulocyte invasion into the brain is a pathoanatomical feature differentiating neuromyelitis optica spectrum disorder (NMOSD) from multiple sclerosis (MS). We aimed to determine whether granulocyte activation markers (GAM) in...
10.
Tanaka E, Watanabe M, Fukumoto S, Masaki K, Yamasaki R, Matsushita T, et al.
Mult Scler Relat Disord
. 2023 Jan;
70:104513.
PMID: 36689892
Background: In relapsing-remitting multiple sclerosis (RRMS), smoking is a known risk factor for disease susceptibility and disability progression. However, its impact on the efficacy of oral disease-modifying drugs (DMDs) is...